产品
编 号:F184270
分子式:C49H48O20
分子量:956.89
产品类型
结构图
CAS No: 155179-21-8
联系客服
产品详情
生物活性:
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis.
体内研究:
钒苷 B (5 mg/kg 或 20 mg/kg; 腹腔注射; 每周 3 次, 共 4 周) 抑制 MDAMB-231 细胞移植的小鼠模型中的肿瘤生长。Animal Model:MDA-MB-231 cell-implanted xenograft mouse model
Dosage:5 mg/kg, 20 mg/kg
Administration:Intraperitoneal injection; 3 times per week over 4 weeks
Result:Significantly reduced tumor volumes at 5 mg/kg and 20 mg/kg by 53.85% and 65.72%, respectively.
体外研究:
钒苷 B (2.5-20 μM; 72 h) 对三阴性乳腺癌 (TNBC) MDA-MB-231 和 HCC38 癌细胞具有抗增殖活性。钒苷 B (2.5-20 μM; 72 h, 14 d 和 72 h) 抑制 TNBC 细胞的细胞活力、集落形成,干扰细胞周期。钒苷 B (2.5-10 μM; 48 h) 降低了 p-STAT1,p-STAT3 和 p-S6 的蛋白水平,并通过调节 Skp2-p27 系列蛋白表达而诱导 TNBC 细胞凋亡。